These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21139283)

  • 1. [Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout].
    Taniguchi A
    Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):330-4. PubMed ID: 21139283
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hyperuricemia. When and how to treat?].
    Reuss-Borst MA
    Internist (Berl); 2016 Feb; 57(2):194-201. PubMed ID: 26791735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Uricosuric agent].
    Ohno I
    Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
    Yamanaka H
    Nihon Rinsho; 2003 Jan; 61 Suppl 1():202-8. PubMed ID: 12629718
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks and benefits of drugs used in the management and prevention of gout.
    Conaghan PG; Day RO
    Drug Saf; 1994 Oct; 11(4):252-8. PubMed ID: 7848545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the treatment options for gout and calcium pyrophosphate deposition.
    Choy G
    Expert Opin Pharmacother; 2005 Nov; 6(14):2443-53. PubMed ID: 16259576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Kolyvanos Naumann U; Suter PM; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Apr; 94(14):543-8; quiz 549. PubMed ID: 15849976
    [No Abstract]   [Full Text] [Related]  

  • 12. Gout in solid organ transplantation: a challenging clinical problem.
    Stamp L; Searle M; O'Donnell J; Chapman P
    Drugs; 2005; 65(18):2593-611. PubMed ID: 16392875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Perez-Ruiz F; Calabozo M; Herrero-Beites AM; García-Erauskin G; Pijoan JI
    Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gout Study Group: update on hyperuricemia and gout.
    Terkeltaub R; Zelman D; Scavulli J; Perez-Ruiz F; Lioté F
    Joint Bone Spine; 2009 Jul; 76(4):444-6. PubMed ID: 19559637
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chronic gout. Case report of a severe course of disease].
    Boxberger F; Harsch IA; Brueckl WM; Hautmann M; Baum U; Hahn EG; Wein A
    Med Klin (Munich); 2003 Nov; 98(11):646-7. PubMed ID: 14631540
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term management of gout: nonpharmacologic and pharmacologic therapies.
    Chaichian Y; Chohan S; Becker MA
    Rheum Dis Clin North Am; 2014 May; 40(2):357-74. PubMed ID: 24703352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of contraindications and prescription of pharmacologic therapies for gout.
    Keenan RT; O'Brien WR; Lee KH; Crittenden DB; Fisher MC; Goldfarb DS; Krasnokutsky S; Oh C; Pillinger MH
    Am J Med; 2011 Feb; 124(2):155-63. PubMed ID: 21295195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy for gout and pseudogout].
    Taniguchi A
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2424-9. PubMed ID: 19149040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.